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0022-2836 © 2008 Eslevier Ltd. Open accOsteopontin plays an important role in the development and perpetuation of
rheumatoid arthritis (RA). Antibodies targeting osteopontin have shown
promising therapeutic benefits against this disease. We have previously
reported a novel anti-RA monoclonal antibody, namely, 23C3, and shown it
capable of alleviating the symptoms of RA in a murine collagen-induced
arthritis model, restoring the cytokine production profile in joint tissues, and
reducing T-cell recall responses to collagen type II. We describe here the
crystal structure of 23C3 in complex with its epitope peptide. Analyses of the
complex structure reveal themolecularmechanismof osteopontin recognition
by 23C3. The peptide folds into two tandem β-turns, and two key residues of
the peptide are identified to be critical for the recognition by 23C3: TrpP43 is
deeply embedded into a hydrophobic pocket formed by AlaL34, TyrL36,
LeuL46,TyrL49, PheL91, andMetH102and thereforehas extensivehydrophobic
interactions with 23C3, while AspP47 has a network of hydrophilic interactions
with residues ArgH50, ArgH52, SerH53, and AsnH56 of the antibody. Besides
the complementarity-determining region loops, the framework region L2 of
23C3 is also shown to interact with the epitope peptide, which is not common in
the antibody–antigen interactions and thus could be exploited in the engineering
of 23C3. These results not only provide valuable information for further
improvement of 23C3 such as chimerization or humanization for its therapeutic
application, but also reveal the features of this specific epitopeof osteopontin that
may be useful for the development of new antibody drugs against RA.
© 2008 Elsevier Ltd.Open access under CC BY license.Keywords: osteopontin; rheumatoid arthritis; 23C3; epitope; antibody
structureEdited by I. WilsonThe pathogenesis of rheumatoid arthritis (RA), a
chronic autoimmune disease, involves accumulation
of T lymphocytes in the synovial compartment and
destruction of cartilage and bone.1–3 Several anti-resses:
.cn.
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ess under CC BY license.rheumatic drugs are available in the market includ-
ing two monoclonal antibody (mAb) drugs against
tumor necrosis factor-α, namely, Infliximab (Cento-
cor) and Adalimumab (Abbott). However, about 20–
30% of the patients treated do not respond to the
antibodies and somedrugs lose efficacy or accumulate
toxicity over time, demanding development of new
strategies for the treatment of RA, probably against
other factors involved in the pathogenesis of RA.4–6
One such target is osteopontin, also known as early
T-cell activation gene-1. It is one of the major non-
collagenous bone matrix proteins and is expressed
at elevated level at the inflammation site in various
836 Structure of the 23C3 Fab–Epitope Peptide Complexcell types including epithelial cells, mesenchymal
cells, and immune cells.7 The protein is usually
phosphorylated and can be cleaved by thrombin in
vivo. When cleaved, the N-terminal fragment is
capable of binding to various cell surface receptors
such as integrins αvβ3, αvβ1, αvβ5, and α8β1 via its
RGD motif,8–10 and α9 and α4 integrins via a crypt
region (162SVVYGLR168 of human osteopontin);11–
13 both the N-terminal and C-terminal fragments can
bind to CD44 variants with the assistance of β1
integrins independently of the RGD sequence.14
Considering the various interactions between osteo-
pontin andmultiple cell receptors, it is not surprising
that osteopontin exerts diverse functions in immu-
nity, infection, and cancer (reviewed in the work of
Denhardt and Guo15). Specifically, the multifaceted
protein is involved in various aspects of immunity:
osteopontin is considered an early component of cell-
mediated immunity16 and seems to play a compli-
cated role in TH2 effector responses
17 and to mediate
natural killer T-cell function.18 Moreover, osteopontin
prevents monocyte apoptosis19 and seems to regulate
the expression of cell-surface CD44 on macrophages
and to modulate CD44 activities.20
An important role of osteopontin in amplification
and perpetuation of RA is suggested by the confined
expression of osteopontin in synovial fluid (SF) and
synovial tissue of RA patients21,22 and the co-
expression of osteopontin receptors (αv, β1 and
CD44) in T cells in SF.21 In addition, when T cells are
treated with RA-SF, osteopontin expression is
elevated; on the other hand, overexpression of
osteopontin induces proinflammatory chemokines
and cytokines and activates nuclear factor-kappa
B.21 Osteopontin deficiency is consistently shown to
prevent the destruction of joint cartilage and joint
swelling through suppression of chondrocyte apop-
tosis and angiogenesis in the RA model.21
Due to the association between osteopontin and
RA, several anti-osteopontin antibodies have been
developed and studies of these antibodies in ani-
mal RA models show promising results.23–25 The
antibody M5 recognizes and binds to a cryptic
epitope of thrombin-cleaved mouse osteopontin
(147SLAYGLR153) and thereby blocks the binding
of cleaved osteopontin to α9 and α4 integrins, which
result in abrogation of monocyte migration.18
Treatment with M5 leads to inhibition of synovial
proliferation, bone resorption, and inflammatory
reaction in arthritic joints in the murine RA model
induced by mAb/lipopolysaccharides.24 Another
mAb, 2K1 or its chimeric form C2K1, recognizes the
equivalent epitope region of human osteopontin
(162SVVYGLR168) and is shown to ameliorate colla-
gen-induced arthritis (CIA) in cynomolgusmonkey.23
Recently, we have developed a novel murine anti-
osteopontin mAb, namely, 23C3, which is of great
potential in treatment of RA.25 Administration of
23C3 to mice with CIA not only strongly suppresses
the development of CIA but also decreases the
severity of the existing arthritis. Mice treated with
23C3 showed a cytokine production profile in joint
tissues similar to that of the wild-type mice andreduced T-cell recall responses to collagen type II.We
have also produced another murine mAb, F8E11,
which is also included for the same assay, however, it
shows much weaker efficacy for the treatment of the
established disease in the murine model.25 As both
F8E11 and 23C3 are capable of inhibiting monocyte
migration, the robust therapeutic effect of 23C3 may
be attributed to its ability to promote the apoptosis of
activated T cells by inhibition of nuclear factor-
kappa B and alteration of the expression of pre-
apoptotic proteins,25 which may be unique, as
neither M5 nor 2K1 is reported to be capable of
induction of cell apoptosis. Intriguingly, 23C3
recognizes a distinct epitope motif (43WLNPDP48)
of the full-length osteopontin, which may account
for the differences.25 In this study, we report the
crystal structure of the Fab fragment of 23C3 in
complex with its epitope peptide of osteopontin.
Our results reveal the structural basis for the 23C3
recognition of osteopontin and provide hints for
further development of mAb drugs for the treatment
of RA.The structure of the 23C3 Fab
The Fab fragment of the anti-osteopontin mAb
23C3 was co-crystallized with a 12-mer peptide
(40VATWLNPDPSQK51) that contains the pre-
viously mapped epitope region of osteopontin
recognized by 23C3.25 The structure of 23C3 Fab
in complex with the epitope peptide was deter-
mined to 2.8 Å resolution with an R−factor of 24.8%
and a free R−factor of 29.2% (Table 1, Fig. 1). There
is one Fab–peptide complex in an asymmetric unit.
Overall, the complex exhibits good geometry and
has well-defined electron density even at the
conserved loop region between GlyH131 and
SerH137, which is disordered in many other Fab
structures.
The Fab fragment displays a canonical Fab struc-
ture with four immunoglobulin domains of VL, CL,
VH, and CH1 (Fig. 1a). The elbow angle relating the
disposition of VH to VL and CH1 to CL is about
150°, consistent with the fact that 23C3 has a κ light
chain.26 The complementarity-determining region
(CDR) loops L1, L2, L3, H1, and H2 belong to
Chothia canonical classes 2, 1, 1, 1, and 4, respec-
tively.27 The CDR loop H3 of 23C3 contains only
five residues, which is significantly shorter than the
average length of 8.7 residues for murine mAbs.28
Interestingly, the Fab is glycosylated at AsnH57 of
CDR H2 (Fig. 1a). An N-linked core tetrasaccharide
(MANα-1,3MANβ-1,4GlcNAcβ-1,4GlcNAcβ-1-
AsnH57) was modeled without ambiguity. N-
linked glycosylation of mAbs in both framework
regions (FWRs)29 and CDR loops30,31 has been
reported, and sugar chains on the CDR loops may
also participate in the interactions with antigens.31
In our structure, there is no interaction between the
sugar chain and the bound peptide. Due to the lack
of a structure of the full-length osteopontin, the
possibility that the sugar chain might be involved
Table 1. Summary of diffraction data and structure
refinement statistics
Diffraction data
Crystal 23C3-epitope
peptide
23C3-W43A
peptide
Wavelength (Å) 1.5418 1.5418
Space group P212121 P212121
Cell parameters
a/b/c (Å) 42.3/92.0/122.5 41.7/92.1/122.1
Resolution range (Å) 20.0–2.80
(2.90–2.80)a
20.0–2.80
(2.90–2.80)
Observed reflections 82,967 (8415) 66,404 (6296)
Unique reflections
[I/σ(I)N0]
12,316 (1192) 12,155 (1171)
Average redundancy 6.7 (7.1) 5.4 (5.3)
Average I/σ(I) 5.0 (2.1) 6.3 (3.1)
Completeness (%) 98.4 (98.4) 99.4 (99.4)
Wilson B-factor (Å2) 58.9 55.6
Rmerge (%)
b 13.5 (29.3) 8.4 (22.9)
Statistics of refinement and model
No. of reflections
[FoN0σ(Fo)]
Working set 11,470 (836) 11,476 (824)
Free R set 613 (32) 609 (35)
R−factor (%)c 24.8 (37.3) 24.1 (31.5)
Free R−factor (%) 29.2 (47.7) 29.7 (39.5)
No. of protein residues 438 436
Fab/Peptide 429/9 429/7
No. of sugar residues 4 4
Average B-factor of all
atoms (Å2)
35.4 33.5
Fab/Peptide 34.8/40.7 33.0/33.2
Sugar 64.2 62.1
r.m.s.d. bond lengths (Å) 0.006 0.010
r.m.s.d. bond angles (°) 1.003 1.171
Luzzati atomic positional
error (Å)
0.46 0.42
Ramachandran plot (%)
Most favored regions 84.9 86.8
Allowed regions 14.0 11.4
Generously allowed
regions
0.3 1.1
Disallowed regions 0.8 0.8
a Numbers in parentheses refer to the highest-resolution shell.
b Rmerge=∑hkl∑i|Ii(hkl)i− 〈I(hkl)〉|/∑hkl∑iIi(hkl).
c R−factor=∑hkl ||Fo|−|Fc||/∑hkl |Fo|.
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be excluded.The structure of the bound peptide
The bound peptide has well-defined electron
density (from ThrP42 to GlnP50) except for several
terminal residues (Fig. 1b). As shown in Fig. 1, the
peptide displays a twisted structure and is com-
posed of the N-terminal two tandem β-turns (β-turn
is the most common structural element of antigens
in mAb–peptide complexes32) and the two C-
terminal extended residues (SerP49 and GlnP50).
The first β-turn (ThrP42 to AsnP45) is of type I and
the second (AsnP45 to ProP48) is of type VIII. The
conformation of the peptide is mainly stabilized by
the interactions between the peptide and the Fab
(see the discussion later), while a hydrogen bond
between the main-chain amide of AspP47 and theside-chain carbonyl of AsnP45 (2.88 Å) also con-
tributes to the stability.The interactions between the Fab and peptide
In the complex structure, the peptide is bound in a
pocket formed by the CDR loops and the tip of the
FWR L2 (defined by Kabat definition). CDR loops
L1, L3, H1, H2, and H3 participate in the interactions
with the peptide, while loop L2 makes no direct
contact with the peptide, as frequently observed in
antipeptide or antihapten Fab structures (Fig. 2a).33
Uncommonly, some residues of the FWR L2
(including TyrL36, LeuL46, and TyrL49) have van
derWaals contacts with the peptide, probably due to
the deep embedment of the side chain of TrpP43 into
the Fab (see detailed discussion later). The buried
surface area (BSA) of the interaction interface is
about 591.3 Å2 within the average range of 400–
700 Å2 for mAb–peptide complexes,34 accounting
for 47.4% of the total peptide surface area. The shape
complementarity value of this complex is 0.80, much
higher than the average value (0.64–0.68) for anti-
body–antigen complexes.35 Between the Fab and the
peptide, nine hydrogen bonds, one salt bridge, and
126 van der Waals contacts are formed (Tables 2 and
S1 and Fig. 2b and c). The CDR loops L1, L3, H1, H2,
and H3 contribute 23.0 Å2 (5.0%), 74.2 Å2 (15.5%),
76.1 Å2 (15.9%), 98.6 Å2 (20.6%), and 132.9 Å2
(27.7%) of the BSA, respectively. Additionally, FWR
L2 also has 74.4 Å2 (15.5%) of the BSA. These results
are consistent with the notion that the H chain
makes more interactions than the L chain when a
mAb binds to a small-molecule antigen or a peptide
antigen.32
Analysis of the complex structure shows that all of
the detected nine residues of the peptide interact
with the 23C3 Fab and, particularly TrpP43 and
AspP47, are the key residues recognized by 23C3.
Specifically, the aromatic residue TrpP43 has a large
hydrophobic indole group buried in a deep hydro-
phobic cage formed by AlaL34, TyrL36, LeuL46,
TyrL49, PheL91, and MetH102, forming 46 van der
Waals contacts and contributing a large BSA of
233.0 Å2 (Fig. 2d). This residue alone contributes
36.5% of all the van der Waals contacts between the
Fab and the peptide and 33.1% of all the BSA of the
peptide. Additionally, the main-chain carbonyl of
TrpP43 forms a hydrogen bond with the side-chain
amide of GlnH101 of CDR loop H3. The acidic
residue AspP47 is embedded into a positively
charged cleft to form electrostatic interactions with
ArgH50 and ArgH52 (Fig. 2e). The side chain of
AspP47 has three hydrogen-bonding interactions
with SerH53 and AsnH56, and its main-chain
carbonyl forms a hydrogen bond with the side
chain of ArgH52 as well. These interactions make
AspP47 the most important contributor for the
hydrophilic interactions between the peptide and
the Fab.
To further validate the critical roles of TrpP43 and
AspP47 in the binding of 23C3, we carried out
Fig. 1. Overall structure of the 23C3 Fab–epitope peptide complex. (a) Stereoview of the overall structure of the 23C3
Fab–epitope peptide complex. The 23C3 Fab light chain is colored yellow, the heavy chain is cyan, and the bound peptide
is purple. The sugar chain is shown with a ball-and-stick model. (b) A stereo view representation of SIGMAA-weighted
2Fo−Fc map (1σ contour level) for the bound epitope peptide. The peptide is shown with a ball-and-stick model.
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839Structure of the 23C3 Fab–Epitope Peptide Complexstructural studies of the 23C3 Fab in complexes with
the mutant peptides containing single mutation
W43A or D47A, or double mutations W43A/
D47A. The crystal structure of the 23C3 Fab in
complex with the W43A mutant peptide was
determined at 2.8 Å resolution with an R−factor of
24.1% and a free R−factor of 29.7% (Table 1). TheFig. 2. The interactions between the 23C3 Fab and the bou
The peptide is bound at a pocket formed mainly by CDRs and
The Fab CDR L1 is colored lemon; L2, salmon; L3, cyan; H1, ora
silver. The peptide is colored purple. (b) A stereo view showing
residues of the epitope peptide. The color coding is the same
bonding interactions are shown with ball-and-stick models. (c
interface. The Fab accommodates the peptide with great stru
hydrophobic interactions between the Fab and the key residue
PheL91 of CDR L3, MetH102 of CDRH3, and TyrL36, LeuL46,
accommodate TrpP43 of the peptide. (e) The hydrophilic reco
bonding interactions with SerH53, AsnH56, and ArgH52. It a
and ArgH52 of CDR H2. The color coding is the same as in (astructure of the mutant complex resembles that of
the wild-type peptide complex (Fig. S1). Super-
position of the two complexes yields an RMSD of
0.4 Å for 436 aligned Cα atoms. In this mutant
peptide complex, only seven (LeuP44 to GlnP50) of
the nine peptide residues (ThrP42 to GlnP50)
observed in the wild-type peptide complex couldnd peptide. (a) An enlarged view of the interface surface.
interacts with CDRs L1, L3, H1, H2, and H3 and FWR L2.
nge; H2, pink; H3, brown; FWR L2, olive; and other FWRs,
the hydrogen bonds between residues of the 23C3 Fab and
as above. The residues that participate in the hydrogen-
) An electrostatic potential surface of the 23C3 Fab at the
ctural and chemical complementarity. (d) The extensive
TrpP43 of the epitope peptide. Residues AlaL34 of CDR L1,
and TyrL49 of FWR L2 form a deep hydrophobic pocket to
gnition of AspP47 by the Fab. AspP47 makes hydrogen-
lso forms electrostatic interactions with residues ArgH50
).
Fig. 2 (legend on previous page)
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Table 2. The hydrophilic interactions between 23C3 Fab
and the peptide
Peptide atoms Fab atoms CDR loops Distance (Å)
TrpP43-O GlnH101-Nε2 H3 2.9
ProP46-O AlaH33-N H1 3.0
AspP47-Oδ1 SerH53-N H2 3.0
AspP47-Oδ1 SerH53-Oγ H2 2.8
AspP47-Oδ1 AsnH56-Nδ2 H2 2.9
AspP47-Oδ2 ArgH52-Nε H2 2.7
AspP47-O ArgH52-Nη1 H2 3.1
SerP49-Oγ ArgH52-Nη1 H2 3.0
GlnP50-Nε2 PheL91-O L3 3.0
841Structure of the 23C3 Fab–Epitope Peptide Complexbe defined with clear electron density and the two
N-terminal residues ThrP42 and AlaP43 are dis-
ordered, indicating that the binding of this region
with the Fab is substantially impaired due to the loss
of the hydrophobic interactions caused by theW43A
mutation. Moreover, crystallization of the 23C3 Fab
in complex with the D47A or W43A/D47A mutant
peptide was unsuccessful so far. It is most likely that
the D47A mutation of the peptide would disrupt the
extensive hydrophilic interactions of the peptide
with the Fab and lead to the loss of the peptide's
ability to bind the Fab. These results support our
notion that TrpP43 and AspP47 are essential for the
binding of 23C3.
Although less important, the other residues within
the mapped epitope 43WLNPDP4825 are also
involved in the binding of the Fab (Fig. 2b, Tables
2 and S1). The side chains of residues LeuP44 and
AsnP45 stretch out against the Fab–peptide interac-
tion interface and each forms 3 van der Waals
contacts. The main-chain carbonyl of ProP46 forms a
hydrogen bond with the main-chain amide of
AlaH33. The side chain of ProP46 is surrounded
by a hydrophobic concave formed by residues
LeuH31 and TyrH32 and forms 14 van der Waals
contacts. The side chain of ProP48 is covered by
AsnP45 and points to the interface forming 7 van der
Waals contacts. Besides the 43WLNPDP48 motif, the
other three residues (ThrP42, SerP49, and GlnP50)
also contribute some van der Waals contacts with
the Fab. The side chains of SerP49 and GlnP50 each
form a hydrogen bond with the side chain of
ArgH52 and the main-chain carbonyl of PheL91,
respectively.
It is worth noting that besides CDRs, three
conserved κ chain residues of FWR L2 (TyrL36,
LeuL46, and TyrL49) are also involved in the
interactions between the peptide and the Fab in
addition to their typical roles in the interactions
betweenVL andVHdomains. In our structure, they all
make van der Waals contacts with the peptide due to
the deep embedment of TrpP43, which is rare, as
residues TyrL36 and LeuL46 generally do not
participate in the Fab–antigen interactions and
TyrL49 is only occasionally found in interactions
between the Fab and nuclear acids or hapten antigens.
In summary, 23C3 is a novel anti-osteopontin
mAbwith great potential for the treatment of RA. By
determination of the crystal structure of 23C3 Fab incomplex with its epitope peptide, we have revealed
the interactions between the antibody and the
peptide and identified the most important determi-
nants for this epitope (TrpP43 and AspP47).We have
also showed that FWR L2 plays an important role in
the recognition and binding of the epitope by the
antibody, suggesting that this region should be
exploited in the development of chimeric or huma-
nized antibodies. Besides, the detailed conformation
of the epitope peptide may also be useful for the
design of peptide vaccines against RA. As an
example, a chemically constrained peptide mimick-
ing the structural conformation of the epitope
peptide of gp41 shows much stronger binding
with the neutralizing HIV antibody 4E10 than the
free peptide and therefore would be a better
immunogen.36
Protein Data Bank accession code
The coordinates and structural factors of the 23C3
Fab fragment in complexes with its epitope peptide
and the W43A mutant peptide have been deposited
in the RCSB Protein Data Bank with accession codes
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